Indeed, EVs isolated from in vitro (i.e., N2a cells expressing aggregation-prone Tau [64]) and in vivo (i.e., brain of Tau transgenic rTg4510 mice [70], CSF derived from AD patients [64,71]) sources can induce Tau aggregation in in vitro systems optimized to assess Tau seeding capacity. The gene discussed is MAPT; the disease is Alzheimer disease.